Report cover image

Global Drugs for HAE Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Feb 07, 2025
Length 171 Pages
SKU # APRC20277681

Description

Summary

According to APO Research, The global Drugs for HAE market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for HAE is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Drugs for HAE is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Drugs for HAE is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Drugs for HAE is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Drugs for HAE include BioCryst Pharmaceuticals, CSL Behring, Pharming Healthcare and Takeda Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs for HAE, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Drugs for HAE, also provides the sales of main regions and countries. Of the upcoming market potential for Drugs for HAE, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for HAE sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Drugs for HAE market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Drugs for HAE sales, projected growth trends, production technology, application and end-user industry.

Drugs for HAE Segment by Company

BioCryst Pharmaceuticals
CSL Behring
Pharming Healthcare
Takeda Pharmaceuticals
Drugs for HAE Segment by Type

C1 Esterase Inhibitors
Bradykinin Receptor Antagonist
Kallikrein Inhibitors
Drugs for HAE Segment by Application

Hospital and Clinic
Pharmacy
Other
Drugs for HAE Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for HAE market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for HAE and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for HAE.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for HAE market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for HAE manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for HAE in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Drugs for HAE in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

171 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Drugs for HAE Market Size, 2020 VS 2024 VS 2031
1.3 Global Drugs for HAE Market Size Estimates and Forecasts (2020-2031)
1.4 Global Drugs for HAE Sales Estimates and Forecasts (2020-2031)
1.5 Global Drugs for HAE Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Drugs for HAE Market Dynamics
2.1 Drugs for HAE Industry Trends
2.2 Drugs for HAE Industry Drivers
2.3 Drugs for HAE Industry Opportunities and Challenges
2.4 Drugs for HAE Industry Restraints
3 Drugs for HAE Market by Manufacturers
3.1 Global Drugs for HAE Revenue by Manufacturers (2020-2025)
3.2 Global Drugs for HAE Sales by Manufacturers (2020-2025)
3.3 Global Drugs for HAE Average Sales Price by Manufacturers (2020-2025)
3.4 Global Drugs for HAE Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Drugs for HAE Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Drugs for HAE Manufacturers, Product Type & Application
3.7 Global Drugs for HAE Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Drugs for HAE Market CR5 and HHI
3.8.2 Global Top 5 and 10 Drugs for HAE Players Market Share by Revenue in 2024
3.8.3 2024 Drugs for HAE Tier 1, Tier 2, and Tier 3
4 Drugs for HAE Market by Type
4.1 Drugs for HAE Type Introduction
4.1.1 C1 Esterase Inhibitors
4.1.2 Bradykinin Receptor Antagonist
4.1.3 Kallikrein Inhibitors
4.2 Global Drugs for HAE Sales by Type
4.2.1 Global Drugs for HAE Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Drugs for HAE Sales by Type (2020-2031)
4.2.3 Global Drugs for HAE Sales Market Share by Type (2020-2031)
4.3 Global Drugs for HAE Revenue by Type
4.3.1 Global Drugs for HAE Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Drugs for HAE Revenue by Type (2020-2031)
4.3.3 Global Drugs for HAE Revenue Market Share by Type (2020-2031)
5 Drugs for HAE Market by Application
5.1 Drugs for HAE Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Drugs for HAE Sales by Application
5.2.1 Global Drugs for HAE Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Drugs for HAE Sales by Application (2020-2031)
5.2.3 Global Drugs for HAE Sales Market Share by Application (2020-2031)
5.3 Global Drugs for HAE Revenue by Application
5.3.1 Global Drugs for HAE Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Drugs for HAE Revenue by Application (2020-2031)
5.3.3 Global Drugs for HAE Revenue Market Share by Application (2020-2031)
6 Global Drugs for HAE Sales by Region
6.1 Global Drugs for HAE Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Drugs for HAE Sales by Region (2020-2031)
6.2.1 Global Drugs for HAE Sales by Region (2020-2025)
6.2.2 Global Drugs for HAE Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Drugs for HAE Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Drugs for HAE Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Drugs for HAE Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Drugs for HAE Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Drugs for HAE Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Drugs for HAE Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Drugs for HAE Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Drugs for HAE Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Drugs for HAE Revenue by Region
7.1 Global Drugs for HAE Revenue by Region
7.1.1 Global Drugs for HAE Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Drugs for HAE Revenue by Region (2020-2025)
7.1.3 Global Drugs for HAE Revenue by Region (2026-2031)
7.1.4 Global Drugs for HAE Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Drugs for HAE Revenue (2020-2031)
7.2.2 North America Drugs for HAE Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Drugs for HAE Revenue (2020-2031)
7.3.2 Europe Drugs for HAE Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Drugs for HAE Revenue (2020-2031)
7.4.2 Asia-Pacific Drugs for HAE Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Drugs for HAE Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Drugs for HAE Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 BioCryst Pharmaceuticals
8.1.1 BioCryst Pharmaceuticals Comapny Information
8.1.2 BioCryst Pharmaceuticals Business Overview
8.1.3 BioCryst Pharmaceuticals Drugs for HAE Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 BioCryst Pharmaceuticals Drugs for HAE Product Portfolio
8.1.5 BioCryst Pharmaceuticals Recent Developments
8.2 CSL Behring
8.2.1 CSL Behring Comapny Information
8.2.2 CSL Behring Business Overview
8.2.3 CSL Behring Drugs for HAE Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 CSL Behring Drugs for HAE Product Portfolio
8.2.5 CSL Behring Recent Developments
8.3 Pharming Healthcare
8.3.1 Pharming Healthcare Comapny Information
8.3.2 Pharming Healthcare Business Overview
8.3.3 Pharming Healthcare Drugs for HAE Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Pharming Healthcare Drugs for HAE Product Portfolio
8.3.5 Pharming Healthcare Recent Developments
8.4 Takeda Pharmaceuticals
8.4.1 Takeda Pharmaceuticals Comapny Information
8.4.2 Takeda Pharmaceuticals Business Overview
8.4.3 Takeda Pharmaceuticals Drugs for HAE Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Takeda Pharmaceuticals Drugs for HAE Product Portfolio
8.4.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Drugs for HAE Value Chain Analysis
9.1.1 Drugs for HAE Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Drugs for HAE Production Mode & Process
9.2 Drugs for HAE Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Drugs for HAE Distributors
9.2.3 Drugs for HAE Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.